FLT3 and acute lymphoblastic leukemia: It is noteworthy that Dovitinib, a multi-functional PTKI with FLT3 inhibitory activity, was reported to exhibit nanomolar in vitro activity against KMT2A/MLL-R+ ALL cells[54].